IRIS
RIZZI, Rita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.573
AS - Asia 4.720
EU - Europa 3.758
SA - Sud America 1.343
AF - Africa 184
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
Totale 20.597
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.434
SG - Singapore 2.060
CN - Cina 1.253
BR - Brasile 1.162
IT - Italia 850
HK - Hong Kong 725
SE - Svezia 667
RU - Federazione Russa 513
UA - Ucraina 443
DE - Germania 426
FI - Finlandia 282
VN - Vietnam 272
GB - Regno Unito 223
FR - Francia 126
IN - India 95
CI - Costa d'Avorio 94
CA - Canada 76
AR - Argentina 66
ID - Indonesia 49
IE - Irlanda 45
BD - Bangladesh 44
MX - Messico 44
TR - Turchia 35
ZA - Sudafrica 35
PL - Polonia 34
NL - Olanda 32
JP - Giappone 31
IQ - Iraq 30
EC - Ecuador 28
BE - Belgio 24
ES - Italia 24
CZ - Repubblica Ceca 21
CO - Colombia 20
VE - Venezuela 17
PY - Paraguay 16
CL - Cile 13
PK - Pakistan 13
AT - Austria 12
MA - Marocco 12
AE - Emirati Arabi Uniti 11
JO - Giordania 11
PE - Perù 11
UZ - Uzbekistan 11
AU - Australia 10
IR - Iran 10
LT - Lituania 9
SA - Arabia Saudita 9
EG - Egitto 8
KE - Kenya 8
KR - Corea 8
AZ - Azerbaigian 7
TN - Tunisia 7
ET - Etiopia 6
UY - Uruguay 6
EU - Europa 5
IL - Israele 5
JM - Giamaica 5
NP - Nepal 5
TW - Taiwan 5
BO - Bolivia 4
BY - Bielorussia 4
GT - Guatemala 4
KZ - Kazakistan 4
RO - Romania 4
SN - Senegal 4
DO - Repubblica Dominicana 3
MY - Malesia 3
OM - Oman 3
PH - Filippine 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AO - Angola 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
CH - Svizzera 2
GA - Gabon 2
HN - Honduras 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MD - Moldavia 2
TG - Togo 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BH - Bahrain 1
BM - Bermuda 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
GI - Gibilterra 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LC - Santa Lucia 1
LY - Libia 1
Totale 20.584
Salva come PNG Salva come JPEG
Città #
Singapore 1.035
Jacksonville 1.017
Chandler 1.011
Ashburn 927
Woodbridge 893
Fairfield 825
Hong Kong 706
Houston 524
Nyköping 470
Ann Arbor 454
Cambridge 431
Seattle 331
Beijing 313
Wilmington 297
Roxbury 256
Lawrence 241
Nanjing 239
Boardman 172
New York 172
Des Moines 161
Los Angeles 151
Dallas 144
Bari 140
Inglewood 107
Abidjan 93
Ho Chi Minh City 90
Princeton 89
São Paulo 84
Brooklyn 76
Shenyang 72
Buffalo 66
Hebei 66
Rome 61
Santa Clara 61
London 57
Hanoi 55
San Diego 55
Dearborn 51
Jiaxing 51
Florence 48
Nanchang 46
Munich 44
Dublin 43
Changsha 41
Milan 38
Moscow 38
Tianjin 37
Nuremberg 34
Paris 34
Guangzhou 33
Jakarta 32
Rio de Janeiro 31
Montreal 28
Helsinki 27
Pune 26
Turku 26
Council Bluffs 25
Tokyo 25
Brasília 24
Belo Horizonte 23
Brussels 23
Phoenix 23
Warsaw 23
Redwood City 22
Toronto 22
Frankfurt am Main 20
Johannesburg 20
San Francisco 20
Chicago 19
Falkenstein 19
Curitiba 18
Jinan 18
Chennai 17
Washington 17
Atlanta 16
Noicattaro 16
Denver 15
Porto Alegre 15
Salvador 15
Shanghai 15
The Dalles 15
Campinas 14
Hefei 14
Kunming 14
Norwalk 13
Stockholm 13
West Jordan 13
Wuhan 13
Ankara 12
Augusta 12
Dhaka 12
Manchester 12
Naples 12
New Delhi 12
Ningbo 12
Santo André 12
Baghdad 11
Biên Hòa 11
Boston 11
Caxias do Sul 11
Totale 13.369
Salva come PNG Salva come JPEG
Nome #
Leucemia linfatica cronica in trasformazione prolinfocitoide: descrizione di un caso 189
LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens 173
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese" 167
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 149
TRAIL effect on osteoclast formation in physiological and pathological conditions 148
A role of light as potential biomarker for progression of smoldering to symptomatic multiple myeloma 145
Non-treatment-related chronic myeloid leukemia as a second malignancy 143
Vascular Endothelial Growth Factor Serum Levels Are Elevated in Patients with Hereditary Hemorrhagic Telangiectasia 137
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients 137
Amyloid in bone marrow smears of patients affected by multiple myeloma 133
CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP) 133
Alteration of the osteogenic properties of bone marrow stromal cells from multiple myeloma bone disease patients 132
Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes 132
A case of AL amyloidosis associated with IgD multiple myeloma (MM): clinical and laboratory findings, and outcome 131
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 130
Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature 128
Sclerostin is overexpressed by plasma cells from multiple myeloma patients 127
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 127
Light/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. 125
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 123
Autoimmune Myelofibrosis: report of three cases and review of the literature 121
ANALYSIS OF PROGNOSTIC FACTORS AND TIME TO FIRST TREATMENT IN YOUNG PATIENTS (<55 YEARS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE 118
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 116
Analysis of percent identity of IGHV mutation as prognostic factor in CLL patients treated with fludarabine, cyclofosfamide and rituximab: a single centre experience 115
A case of light chain (AL) amyloidosis associated with IgD Multiple Myeloma (MM): clinical features, laboratory findings and outcome 114
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 114
Rhabdomyolysis and acute tubular necrosis in coniine (hemlock)poisoning 112
CD34CD2 Acute promyelocytic leukemia (APL): is this a distinct subset? 112
Takayasu’s arteritis: a cell mediated large vessel vasculitis 111
Hepatitis C virus infection and mixed cryoglobulinemia: a striking association 111
Another link between bone and immune system: LIGHT 110
Anti-endothelial cell antibodies (AECA) in a patient wiyh Takayasu’s arteritis. In: Pathogenesis and immunotherapy of autoimmune diseases. Final program and abstract book 109
Ibridizzazione in situ non isotopica. Attualità e prospettive 109
A rare case of IgM-Multiple Myeloma 109
Altered osteogenic properties of bone marrow stromal cells from multiple myeloma patients 109
Alteration of bone remodeling in multiple myeloma bone disease: role of sclerostin 108
The role of multiparameter flow cytometry in the work-up of IGM-monoclonal gammopathies 108
A weekly infusion of bortezomib reduces peripheral neuropathy 108
Soluble Decoy Receptor 3 (DcR3) modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients 106
Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients 106
In vitro osteoclastogenesis and T-cell RANKL expression in multiple myeloma-bone disease at diagnosis and in the setting of frontline treatment 105
Autoimmune hemolytic anemia during interferon-alfa therapy for chronic hepatitis C 105
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase 105
LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients 105
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 104
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 104
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction 103
DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION 102
Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion 102
A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up 102
The OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 102
Malignant lymphoma involving a Warthin’s tumor: a case with immunophenotypic and gene rearrangement analysis 100
Acute tubular necrosis in the hemlock poisoning 100
Infection complications in patients with multiple myeloma treated with new drug combinations including thalidomide 100
The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 99
Livelli sierici di VEGF in pazienti affetti da Sindrome di Rendu-Osler-Weber 99
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia 99
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 99
Myeloma cells suppress osteoblasts through sclerostin secretion 98
A phase II Study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis 97
The Role of LIGHT in Multiple Myeloma-Bone Disease 97
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 96
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 96
Alterazione delle capacità osteogeniche in cellule stromali ottenute da midollo osseo di pazienti affetti da mieloma multiplo 95
Immunogenicity of two idiotypes with a different immunoglobulin-chain distribution expressed on the same anti-CD4 Mab 94
Bone marrow angiogenesis in autoimmune myelofibrosis 94
A phase II study of chlorambucil + rituximab (CLB-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results 94
T cells support osteoclastogenesis in an in vitro model derived from psoritic arthritis 93
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience 93
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 92
T cells support the in vitro formation of osteoclasts in multiple myeloma-bone disease: the role of OPG/TRAIL interaction 92
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 91
Cost of illness in patients with multiple myeloma in Italy: the CoMiM study 91
DCR3 involvement in multiple myeloma bone disease 91
Anti-endothelial cell autoantibodies in patients with Behcet’s disease 91
LIGHT INVOLVEMENT IN MULTIPLE MYELOMA-OSTEOLYTIC BONE DISEASE 91
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function 90
Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma 90
A Phase III study of enoxaparin versus aspirin versus low-dose warfarin as thrombophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide based-regimens 89
Angiogenesis and hereditary hemorrhagic telangiectasia. Rendu-Osler-Weber disease 89
P-ANCA atipici nelle malattie infiammatorie croniche intestinali 88
T cells support the osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease 87
L'AMILOIDOSI: QUADRI CLINICI, CARATTERISTICHE IMMUNOLOGICHE E BIOMOLECOLARI, PROSPETTIVE TERAPEUTICHE 87
Aneurysms of the supra-aortic trunks in Takayasu's disease - Report of two cases 87
Autoimmune bone marrow fibrosis: a distinct clinicopathological entity 86
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide 86
Clinical spectrum of accidental hemlock poisoning: neurotoxic manifestations, rhabdomyolysis and acute tubular necrosis 86
Schnitzler's syndrome: diagnosis, treatment, and follow-up. 86
Failure of an in vitro model of osteoclastogenesis in human plasma cell leukaemia (PCL) 86
Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific? 86
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. 85
Microvessel density and angiogenic cytokine expression in autoimmune myelofibrosis compared with chronic idiopathic myelofibrosis 84
The role of the Wnt-signaling antagonist Sclerostin in the development of osteolytic lesions in multiple myeloma 84
Myeloma cells induce osteoblast suppression through sclerostin secretion 84
Circulating levels of cathepsin-k in multiple myeloma patients 84
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma 84
What Is New in the Treatment of Smoldering Multiple Myeloma? 84
Kidney damage by ingestion of ethylene glicol 83
Human anti-mouse antibodies interfere in the determination of sCD4 in intravenous immunoglobulin preparations 83
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 83
Totale 10.617
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.321
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.148 0 0 0 0 0 101 234 126 204 242 151 90
2021/20221.790 78 253 7 128 56 77 73 96 126 79 314 503
2022/20232.648 380 231 111 271 344 375 41 300 495 16 45 39
2023/20241.332 200 212 73 66 97 238 65 69 8 55 101 148
2024/20254.078 114 55 403 140 110 366 310 344 182 187 622 1.245
2025/20264.101 1.181 365 575 970 859 151 0 0 0 0 0 0
Totale 20.934